David Ritchie has M.D. and Ph.D. degrees. He holds a coappointment as a Consultant Haematologist and BMT Physician at the Royal Melbourne Hospital (RMH), Parkville, VIC, Australia, and Peter MacCallum Cancer Centre (PMCC), East Melbourne, VIC, Australia. He also serves as a Cohead of the Haematology Immunology Translational Research Laboratory (HITRL). Ritchie works as the Director of the ACRF Translational Haematology and Cancer Laboratory, the Current President of the Haematology Society of Australia and New Zealand, and Chair of the BMT Study Group of the Australasian Lymphoma and Leukaemia Group (ALLG). His clinical and translational research is specifically on the immunology and immunotherapy of blood cancers and the immunology of new drug therapies in myelodysplasia (MDS), acute and chronic leukaemias, myeloma and lymphoma, and the immunology of allogeneic transplantation. He has extensive experience as a Principal Investigator of numerous investigator-initiated and company-sponsored phases I-III clinical trials and substantial experience of the design and undertaking of clinical and translational research. Ritchie has published and presented his work widely with over 100 peer-reviewed publications and presentations at international meetings including ASH, EHA, EBMT, and HAA.
Biography Updated on 2 October 2013